Companies view Sunshine differently

Share this article:
Pfizer
Pfizer

A report by PMLive indicates that pharmaceutical companies have distinct views on what the Sunshine Act requires.

According to a presentation made at the International Society for Medical Publications Professionals, PMLive noted, for example, that Pfizer and AstraZeneca report payments for medical writing. The companies said they report the payments because the publications represent value for the company and author.

Shire's publications director Antonia Panayi, though, said her company does not consider these publications reportable because the value is limited to pharma, as opposed to being beneficial for professionals.

Panayi said the value is limited to “what has already been paid as part of their contractual agreement for the trial,” and that author “kudos” for publication would be difficult to quantify.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.